The current and emerging role of immunotherapy in prostate cancer

Clinical Genitourinary Cancer

Volumn 8, Issue 1, 2010, Pages 10-16

  Madan, Ravi ^a   Gulley, James ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer Vaccine; Treatment

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; CANCER VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IPILIMUMAB; KETOCONAZOLE; PLACEBO; PROSTVAC; PROVENGE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN RECOGNITION; B LYMPHOCYTE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; DISEASE COURSE; DRUG TARGETING; HUMAN; IMMUNE RESPONSE; IMMUNOREACTIVITY; IMMUNOSTIMULATION; NATURAL KILLER CELL; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; REVIEW; T LYMPHOCYTE; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 78651103349     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.3816/CGC.2010.n.002     Document Type: Review

References (74)

1. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351:1502-12.
2. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351:1513-20.
3. Sartor A, Oudard S, Ozguroglu M, et al. Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results of a multinational phase III trial (TROPIC). Presented at: ASCO Genitourinary Cancers Symposium; March 5-7, 2010; San Francisco, California (Abstract 9).
4. FDA approves a cellular immunotherapy for men with advanced prostate cancer. April 29, 2010. Available at: Http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm210174.htm. Accessed: June 7, 2010.
5. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324:787-90.
6. Madan RA, Arlen PM. Abiraterone. Cougar Biotechnology. IDrugs 2006; 9:49-55.
7. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005; 294:238-44.
8. Rotow J, Gameiro SR, Madan RA, et al. Vaccines as monotherapy and in combination therapy for prostate cancer. Clin Transl Sci 2010; 3:116-22.
9. Gulley JL, Arlen PM, Bastian A, et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 2005; 11:3353-62.
10. FDAPrescribing Information for Provenge. Available at: Http://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ ApprovedProducts/UCM210031.pdf. Accessed: October 1, 2010.
11. Rini BI. Technology evaluation: APC-8015, Dendreon. Curr Opin Mol Ther 2002; 4:76-9.
12. Patel PH, Kockler DR. Sipuleucel-T: A vaccine for metastatic, asymptomatic, androgen-independent prostate cancer. Ann Pharmacother 2008; 42:91-8.
13. Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000; 18:3894-903.
14. Burch PA, Croghan GA, Gastineau DA, et al. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: A phase 2 trial. Prostate 2004; 60:197-204.
15. Beinart G, Rini BI, Weinberg V, et al. Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer. Clin Prostate Cancer 2005; 4:55-60.
16. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24:3089-94.
17. Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009; 115:3670-9.
18. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-22.
19. Madan RA, Arlen PM, Mohebtash M, et al. Prostvac-VF: A vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs 2009; 18:1001-11.
20. Essajee S, Kaufman HL. Poxvirus vaccines for cancer and HIV therapy. Expert Opin Biol Ther 2004; 4:575-88.
21. Gulley J, Chen AP, Dahut W, et al. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate 2002; 53:109-17.
22. Kaufman HL, Wang W, Manola J, et al. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): A trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2004; 22:2122-32.
23. Arlen PM, Skarupa L, Pazdur M, et al. Clinical safety of a viral vector based prostate cancer vaccine strategy. J Urol 2007; 178:1515-20.
24. DiPaola R, Chen Y, Bubley G, et al. A phase II study of PROSTVAC-V (vaccinia)/TRICOM and PROSTVAC-F (fowlpox)/TRICOM with GM-CSF in patients with PSA progression after local therapy for prostate cancer: Results of ECOG 9802. Presented at: ASCO Genitourinary Cancers Symposium; February 26-28, 2009; Orlando, Florida (Abstract 108).
25. Hodge JW, Sabzevari H, Yafal AG, et al. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res 1999; 59:5800-7.
26. Aarts WM, Schlom J, Hodge JW. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. Cancer Res 2002; 62:5770-7.
27. Grosenbach DW, Barrientos JC, Schlom J, et al. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. Cancer Res 2001; 61:4497-505.
28. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28:1099-105.
29. Gulley JL, Arlen PM, Madan RA, et al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother 2010; 59:663-74.
30. PROSTVAC: Therapeutic vaccine candidate for the treatment of advanced prostate cancer. Available at: Http://www.bavarian-nordic.com/pipeline/prostvac. aspx. Accessed: July 20, 2010.
31. Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995; 270:985-8.
32. Egen JG, Kuhns MS, Allison JP. CTLA-4: New insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002; 3:611-8.
33. Allison JP, Chambers C, Hurwitz A, et al. A role for CTLA-4-mediated inhibitory signals in peripheral T cell tolerance? Novartis Found Symp 1998; 215:92-8; discussion 8-102, 86-90.
34. Hodge JW, Chakraborty M, Kudo-Saito C, et al. Multiple costimulatory modalities enhance CTL avidity. J Immunol 2005; 174:5994-6004.
35. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23.
36. Small EJ, Tchekmedyian NS, Rini BI, et al. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 2007; 13:1810-5.
37. Gerritsen W, van den Eertwegh A, de Gruijl T, et al. Expanded phase I combination trial of GVAX immunotherapy for prostate cancer and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHPRC). J Clin Oncol 2008; 26(15 suppl):285s (abstract 5146).
38. Madan R, Mohebtash M, Arlen P, et al. Overall survival analysis of a phase l trial of a vector-based vaccine (PSA-TRICOM) and ipilimumab in the treatment of metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28(15 suppl):216s (abstract 2550).
39. Study of Immunotherapy to Treat Advanced Prostate Cancer. Available from: July 17, 2010. http://www.clinicaltrials.gov/ct2/show/NCT00861614?term= ipilimumab+prostate&rank=6
40. Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer. Available at: Http://clinicaltrials.gov/ct2/show/NCT01057810?term= ipilimumab+prostate&rank=3. Accessed: August 5, 2010.
41. Ryan JE, Ovsyannikova IG, Dhiman N, et al. Inter-operator variation in ELISPOT analysis of measles virus-specific IFN-gamma-secreting T cells. Scand J Clin Lab Invest 2005; 65:681-9.
42. Cox JH, Ferrari G, Kalams SA, et al. Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials. AIDS Res Hum Retroviruses 2005; 21:68-81.
43. Stein WD, Figg WD, Dahut W, et al. Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: A novel strategy for evaluation of clinical trial data. Oncologist 2008; 13:1046-54.
44. Fojo A, Stein W, Wilkerson J, et al. Kinetic analysis of breast tumor decay and growth following ixabepilone plus capecitabine (IXA + CAP) versus capecitabine alone (CAP) to discern whether the superiority of the combination is a result of slower growth, enhanced tumor cell kill, or both. J Clin Oncol 2010; 28(15 suppl):137s (abstract 1096).
45. Wilkerson J, Stein W, Kim S, et al. Validation of a kinetic analysis of renal cancer regression and growth following treatment with sunitinib and interferon-alfa (IFN-alpha): Analysis of the pivotal randomized trial. J Clin Oncol 2010; 28(15 suppl):366s (abstract 4597).
46. Gulley J, Stein W, Schlom J, et al. A retrospective analysis of intramural NCI prostate cancer trials: Progress made and insights gleaned. J Clin Oncol 2010; 28(15 suppl):380s (abstract 4657).
47. Stein WD, Gulley J, Schlom J, et al. Tumor regression and growth rates determined in five intramural NCI prostate cancer trials. The growth rate as an indicator of therapeutic efficacy. Clin Cancer Res 2010; November 24 [Epub ahead of print].
48. Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003; 21:1232-7.
49. Piccirillo CA, Shevach EM. Cutting edge: Control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol 2001; 167:1137-40.
50. Woo EY, Yeh H, Chu CS, et al. Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002; 168:4272-6.
51. Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155:1151-64.
52. Morse MA, Clay TM, Mosca P, et al. Immunoregulatory T cells in cancer immunotherapy. Expert Opin Biol Ther 2002; 2:827-34.
53. Sakaguchi S. Regulatory T cells: Key controllers of immunologic self-tolerance. Cell 2000; 101:455-8.
54. Madan R, Vergati M, Cereda P, et al. Changes in regulatory T cell function and overall survival in metastatic castration resistant prostate cancer (mCRPC) patients treated with a vector-based vaccine [poster presentation]. Presented at: AACR Annual Meeting; April 18-22, 2009; Denver, Colorado (Abstract 726).
55. Halabi S, Vogelzang NJ, Kornblith AB, et al. Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol 2008; 26:2544-9.
56. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26:1148-59.
57. Yang S, Hodge JW, Grosenbach DW, et al. Vaccines with enhanced co-stimulation maintain high avidity memory CTL. J Immunol 2005; 175:3715-23.
58. Mercader M, Bodner BK, Moser MT, et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A 2001; 98:14565-70.
59. Aragon-Ching JB, Williams KM, Gulley JL. Impact of androgen-deprivation therapy on the immune system: Implications for combination therapy of prostate cancer. Front Biosci 2007; 12:4957-71.
60. Drake CG, Doody AD, Mihalyo MA, et al. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell 2005; 7:239-49.
61. Chan OT, Yang LX. The immunological effects of taxanes. Cancer Immunol Immunother 2000; 49:181-5.
62. Garnett CT, Schlom J, Hodge JW. Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: Effects of docetaxel on immune enhancement. Clin Cancer Res 2008; 14:3536-44.
63. Gribben JG, Ryan DP, Boyajian R, et al. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res 2005; 11:4430-6.
64. Antonia SJ, Mirza N, Fricke I, et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 2006; 12:878-87.
65. Petrylak D. Defining the optimal role of immunotherapy and chemotherapy: Advanced prostate cancer patients who receive sipuleucel-T (Provenge) followed by docetaxel derive greatest survival benefit [abstract]. Presented at: Chemotherapy Foundation Symposium 14th Annual Meeting; November 8-11, 2006; New York, NY.
66. Madan RA, Gulley JL, Schlom J, et al. Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. Clin Cancer Res 2008; 14:4526-31.
67. Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer. Available at: Http://ecog.dfci.harvard.edu/active-reports/Genitourinary.html. Accessed: August 16, 2010.
68. Vaccine therapy with PROSTVAC/TRICOM and flutamide versus flutamide alone to treat prostate cancer. Available at: Http://clinicaltrials.gov/ct2/show/ NCT00450463?term=Prostvac&rank=2. Accessed: July 21, 2010.
69. Quarmby S, Hunter RD, Kumar S. Irradiation induced expression of CD31, ICAM-1 and VCAM-1 in human microvascular endothelial cells. Anticancer Res 2000; 20:3375-81.
70. Friedman EJ. Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr Pharm Des 2002; 8:1765-80.
71. Chakraborty M, Abrams SI, Camphausen K, et al. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol 2003; 170:6338-47.
72. Chakraborty M, Abrams SI, Coleman CN, et al. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res 2004; 64:4328-37.
73. Petersen LJ, Lund L, Jonler M, et al. Samarium-153 treatment of bone pain in patients with metastatic prostate cancer. Dan Med Bull 2010; 57:A4154.
74. 153Sm-EDTMP with or without a PSA/TRICOM vaccine to treat men with androgen-insensitive prostate cancer. Available at: Http://clinicaltrials.gov/ ct2/show/NCT00450619?term=samarium-153&rank=13. Accessed: August 5, 2010.